Tumor cell vaccine

The present disclosure provides an allogeneic whole cell cancer vaccine platform, including compositions and methods for treating and preventing cancer. Provided herein are compositions comprising a therapeutically effective amount of cells from one or more cancer cell lines, some or all of which are modified to (i) inhibit or reduce cell expression of one or more immunosuppressive factors; and/or (ii) express or increase the expression of the cell on one or more immunostimulating factors, and/or (iii) express or increase the expression of one or more tumor associated antigens (TAAs), including mutated TAAs, and the cancer cell line comprises cancer cell lines that naturally express heterogeneity tumor associated antigens and/or neoantigens, and/or (ii) express or increase the expression of the cell on one or more immunostimulating factors, and/or (iii) express or increase the expression of tumor associated antigens (TAAs), including mutated TAAs, and the cancer cell line comprises cancer cell lines that natu